Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE: Treatments being monitored by RAPID C-19 |
|
Medicine details |
|
Medicine name | regdanvimab (Regkirona®) |
Formulation | 60 mg/mL concentrate for solution for infusion |
Reference number | 5034 |
Indication | Treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 |
Company | Celltrion Healthcare Co Ltd |
BNF chapter | Infections |
Assessment type | N/A |
Status | Excluded due to NICE appraisal |
Date of issue | 13/01/2022 |
NICE guidance |